The European Commission (EC) has approved Empliciti (elotuzumab) in combination with Pomalyst (pomalidomide) and low-dose…
Articles by Joana Carvalho, PhD
Using a combination of CAR T-cell therapies to target different cancer molecules appears to be a feasible and promising way of…
The Committee for Medicinal Products for Human Use (CHMP), a branch of the European Medicines Agency (EMA), has…
Janssen has asked the U.S. Food and Drug Administration (FDA) to approve a new subcutaneous (under-the-skin) formulation of…
The U.S. Food and Drug Administration (FDA) has approved — with conditions — Xpovio (selinexor) tablets, in…
Scientists discovered a set of genes that work as an “on/off switch” for malignant multiple myeloma cancer cells, which…
The U.S. Food and Drug Administration (FDA) has approved Janssen‘s Darzalex (daratumumab), used…
Selinexor in combination with dexamethasone and Pomalyst (pomalidomide) leads to strong and durable anti-cancer responses, without significant…
CT103A, a fully-human anti-B-cell mature antigen (BCMA) CAR T-cell therapy, leads to strong anti-cancer responses in patients with…
Ygalo (melflufen) combination therapy continues to lead to clinically meaningful responses, without significant side effects, in patients with…